

Special Issue

Recent Trends in Preclinical Models for Inhalation and Nasal Drug Delivery

Message from the Guest Editors

Nebulizers are widely used in medicine to treat asthma, COPD, and cystic fibrosis patients. They generate fine droplets from a liquid drug to be delivered in the airways. Recent advances in nebulizer technologies trend to reduce their size, to make them more portable and e-connected. The frontier between new nebulizers and metered dose inhalers (pMDI and DPI) is disappearing. New nebulizers are becoming more and more efficient and packaged with the drug. From a clinical point of view, recent advances have demonstrated the ability of nebulizers to be used in complicated situations, like mechanical ventilation, newborns and nasal high flow. They are also considered for nasal treatment and more particularly for chronic rhinosinusitis patients to target sinuses. Some nebulizers are open devices and offer the opportunity to rapidly evaluate a new drug or a new indication, reducing the time to market and the benefit for the patient. This Special Issue shall cover recent trends in nebulizer device design and clinical use.

Guest Editors

Dr. Laurent Vecellio

Research Centre for Respiratory Diseases, University of Tours, 37000 Tours, France

Dr. Frédéric Ducancel

Centre de Recherche de Fontenay-aux-Roses, CEA, 18 Route du Panorama, 92260 Fontenay-aux-Roses, France

Deadline for manuscript submissions

closed (30 November 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/37243

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).